+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying a treatment for adults with muscle-invasive bladder cancer, a condition where cancer has spread into the muscle wall of the bladder. The usual approach involves chemotherapy followed by bladder removal surgery, which can cause significant long-term changes. This study focuses on using a combination of enfortumab vedotin and pembrolizumab to help people keep their bladder, especially for those who respond well to this therapy and wish to avoid surgery. Participants will receive infusions of enfortumab vedotin on the 1st and 8th days of every 3-week cycle, along with pembrolizumab on the 1st day of each cycle. Treatment continues unless the cancer worsens, does not improve after 9 cycles, or if other medical reasons arise. Those whose cancer does not respond may need surgery, radiotherapy, or chemotherapy. The study monitors safety and tumor status regularly during these cycles. Throughout the study, participants will have safety checks at each visit, tumor assessments at some visits, and medical monitoring. After stopping treatment, health checks and scans occur every 3 months for 2 years, then every 6 months for up to 5 years if the cancer remains stable. Once cancer progresses, scans stop, but telephone health checks continue every 3 months. The main outcomes measured are the rate of complete response to treatment and the duration participants keep their bladder intact over two years.

Age: 18Years +All GendersPhase 2
68 locations